Drug Trial Radar · NCT06846515
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
866
Actual
Start
Mar 11, 2025
Primary completion
Aug 31, 2026
Study completion Sep 18, 2026
Sponsor
- Lead sponsor
- Arthrosi TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Feb 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Conditions
- Gout
- Arthritis, Gouty
- Hyperuricemia
- Gout Chronic
Interventions
AR882 50 mgDrug
Solid Oral Capsule
AR882 75 mgDrug
Solid Oral Capsule
PlaceboDrug
Matching Solid Oral Capsule Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Serum urate (uric acid) (sUA) level < 6 mg/dL at month 6Time frame: 24 weeks
Locations
83 sites in 1 country. Site status is shown where the registry gives one.
Arthrosi Investigative Site (620)
Birmingham, Alabama
Arthrosi Investigative Site (616)
Huntsville, Alabama
Arthrosi Investigative Site (680)
Peoria, Arizona
Arthrosi Investigative Site (640)
Phoenix, Arizona
Arthrosi Investigative Site (617)
Little Rock, Arkansas
Arthrosi Investigative Site (614)
Garden Grove, California
Arthrosi Investigative Site (618)
La Mesa, California
Arthrosi Investigative Site (687)
La Mesa, California
Arthrosi Investigative Site (655)
La Palma, California
Arthrosi Investigative Site (632)
Lincoln, California
Arthrosi Investigative Site (605)
Lomita, California
Arthrosi Investigative Site (675)
Long Beach, California
Arthrosi Investigative Site (603)
Santa Monica, California
Arthrosi Investigative Site (672)
Tarzana, California
Arthrosi Investigative Site (656)
Thousand Oaks, California
Arthrosi Investigative Site (660)
Aurora, Colorado
Arthrosi Investigative Site (669)
Colorado Springs, Colorado
Arthrosi Investigative Site (612)
Fort Collins, Colorado
Arthrosi Investigative Site (665)
Cooper City, Florida
Arthrosi Investigative Site (613)
Jupiter, Florida
Arthrosi Investigative Site (611)
Miami, Florida
Arthrosi Investigative Site (644)
Miami, Florida
Arthrosi Investigative Site (694)
Palmetto Bay, Florida
Arthrosi Investigative Site (615)
Sanford, Florida
Arthrosi Investigative Site (600)
Tampa, Florida
Arthrosi Investigative Site (673)
Atlanta, Georgia
Arthrosi Investigative Site (652)
Marietta, Georgia
Arthrosi Investigative Site (658)
Honolulu, Hawaii
Arthrosi Investigative Site (676)
Boise, Idaho
Arthrosi Investigative Site (634)
Meridian, Idaho
Arthrosi Investigative Site (657)
Chicago, Illinois
Arthrosi Investigative Site (648)
Melrose Park, Illinois
Arthrosi Investigative Site (678)
Indianapolis, Indiana
Arthrosi Investigative Site (679)
Overland Park, Kansas
Arthrosi Investigative Site (674)
Louisville, Kentucky
Arthrosi Investigative Site (627)
Mandeville, Louisiana
Arthrosi Investigative Site (650)
New Orleans, Louisiana
Arthrosi Investigative Site (641)
Prairieville, Louisiana
Arthrosi Investigative Site (662)
Oxon Hill, Maryland
Arthrosi Investigative Site (653)
Rockville, Maryland
Showing 40 of 83 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.